Cooperative Agreement UM1DA064499
Award Date 9/15/25
Completion Date 5/31/30
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, is for a project titled "Strengthening Buprenorphine Treatment for Individuals in Carceral Settings (STAND): A Hybrid Implementation-Effectiveness Trial of Long-Acting Injectable versus Sublingual Buprenorphine." The project aims to conduct a large randomized controlled trial comparing the effectiveness of long-acting injectable buprenorphine versus sublingual...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $201,960 Project Grant to the University of Utah under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The funding supports a research study titled "Building Evidence for Effective Extended-Release Buprenorphine Treatment for Opioid Use Disorder." The goal is to generate evidence on the optimal use of extended-release buprenorphine, a newer medication-based...
- This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention aimed at increasing treatment uptake for patients with opioid use disorder (OUD) and nonfatal opioid overdoses after emergency department (ED) discharge. The proposed intervention combines telehealth, peer support, buprenorphine prescribing, and linkage to...
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,932,500.00 in funding to The Drug Delivery Company, LLC to develop a bioabsorbable, subcutaneous, extended-release buprenorphine implant for the treatment of opioid use disorder. The project aims to build upon the company's successful development of a 6-month bioabsorbable naltrexone implant, known as ISTEP-N, which demonstrated the...
- This federal Project Grant award of $739,353 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a study to develop an effective and efficient multicomponent intervention to increase buprenorphine treatment retention for individuals with opioid use disorder. The study, titled "BUP - BOOSTER: Behavioral Optimization for Overcoming Suboptimal Treatment Retention," will test the impact of three psychosocial...
- This $147,486 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will support a mixed-methods study examining the predictors and outcomes of methadone and buprenorphine receipt during incarceration. The study will analyze a longitudinal database on health service use and outcomes among 4,558 incarcerated individuals who received these medications from 2016-2023 at a unified jail and prison system in the Northeast....
- The National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, awarded a $1,548,605 Project Grant to the University of Massachusetts Medical School (UMMS) to test the effectiveness of the Jail ECHO Operations, Planning, and Strategy (J-ECHO OPS) implementation strategy to increase access to Medication for Opioid Use Disorder (MOUD) in rural jails. The study, titled "Improving Jail Response to the Overdose Crisis: A Hybrid Trial of Jail...
- This federal Cooperative Agreement award of $680,100 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is intended to investigate the use of a combined transcranial direct current stimulation (tDCS) and cognitive training intervention as an adjunct treatment for individuals with opioid use disorder (OUD) who are receiving buprenorphine maintenance treatment. The key products and services to be delivered under this award include:...
- The National Institute on Drug Abuse (NIDA) awarded a $2,729,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Rhode Island. The purpose of this 2-year award, with a start date of September 15, 2024, is to rigorously develop and evaluate a mobile health intervention for adults with co-occurring opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) during community re-entry after residential OUD treatment. The proposed mobile app...
- The National Institute on Drug Abuse (NIDA) has awarded a $731,275 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Massachusetts Medical School (UMMS) to support the "Supporting Treatment Access and Recovery in Re-entry (STAR-R)" study. The 5-year study will evaluate the effectiveness of the "Maintaining Independence and Sobriety through Systems Integration, Outreach, and Networking-Criminal Justice Version (MISSION-CJ)"...